MESO - Mesoblast Ltd logo

MESO

Mesoblast Ltd

Net β€”top 1%Rev β€”top 1%10Y
Hold

Mesoblast Ltd develops regenerative medicine products utilizing mesenchymal lineage cells. Its lead candidate, Remestemcel-L, targets systemic inflammatory diseases and chronic conditions. The company collaborates on various therapies for heart failure and arthritis.

βš•οΈ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago β†’$1,283today

Score Overview

1 Year
Scoreβ€”
Net Growthβ€”
Net Trendβ€”
Net Income Consistencyβ€”
Rev Growthβ€”
Rev Trendβ€”
Revenue Consistencyβ€”
5 Years
Scoreβ€”
Net Growthβ€”
Net Trend50%
Net Income Consistencyβ€”
Rev Growthβ€”
Rev Trend50%
Revenue Consistencyβ€”
10 Years
Scoreβ€”
Net Growthβ€”
Net Trend44%
Net Income Consistency
Rev Growthβ€”
Rev Trend44%
Revenue Consistency
All Time
Scoreβ€”
Net Growthβ€”
Net Trend44%
Net Income Consistency
Rev Growthβ€”
Rev Trend44%
Revenue Consistency

See the full market ranking β†’

Mesoblast Ltd fundamental performance

Across Mesoblast Ltd's full reported history, from 2016 to 2025, revenue declined from $ 42M to $ 17M and net income went from -$ 4M to -$ 102M. Revenue increased in 44% of the years measured; net income in 44%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 16.78β€”
1 Year2025-08-12
$ 14.8513.00%
5 Years2021-08-12
$ 15.2410.10%
10 Years2016-08-12
$ 13.0828.29%
All Time2015-11-13
$ 16.223.45%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026
2025$ 17M-$ 102M$ 161M
2024$ 5M-$ 87M$ 62M
2023$ 7M-$ 81M$ 70M
2022$ 10M-$ 91M$ 60M
2021$ 7M-$ 98M$ 136M
2020$ 32M-$ 77M$ 129M
2019$ 16M-$ 89M$ 50M
2018$ 17M-$ 35M$ 37M
2017$ 2M-$ 76M$ 45M
2016$ 42M-$ 4M$ 21M

Explore beyond MESO

You're looking at Mesoblast Ltd. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies